We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-6.2%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.77B
AUM Growth
-$356M
Cap. Flow
-$1.35B
Cap. Flow %
-28.26%
Top 10 Hldgs %
39.93%
Holding
155
New
23
Increased
16
Reduced
21
Closed
28

Top Buys

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$89.6M
2
AHCO icon
AdaptHealth
AHCO
+$49.8M
3
ESPR
Esperion Therapeutics
ESPR
+$40M
4
XLO icon
Xilio Therapeutics
XLO
+$36.7M
5
FIGS icon
FIGS
FIGS
+$27.3M

Top Sells

Rank Stock Value
1
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$30.8M
2
MOH icon
Molina Healthcare
MOH
+$28.8M
3
CYTK icon
Cytokinetics
CYTK
+$28.1M
4
XLRN
Acceleron Pharma
XLRN
+$25M
5
FATE icon
Fate Therapeutics
FATE
+$21.5M

Sector Composition

Rank Sector Weight
1 Healthcare 62.96%
2 Financials 1.4%
3 Consumer Discretionary 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTCR
126
DELISTED
Metacrine, Inc. Common Stock
MTCR
– –
-277,469
Closed -$952K
SRSAU
127
DELISTED
Sarissa Capital Acquisition Corp. Unit
SRSAU
– –
-1,000,000
Closed -$9.88M
TMPMU
128
DELISTED
Turmeric Acquisition Corp. Unit
TMPMU
– –
-750,000
Closed -$7.45M
TPTX
129
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-83,846
Closed -$5.57M
ITMR
130
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
– –
-694,667
Closed -$21M
XLRN
131
DELISTED
Acceleron Pharma
XLRN
– –
-145,000
Closed -$25M
MAACW
132
DELISTED
Montes Archimedes Acquisition Corp. Warrant
MAACW
– –
-1,000,000
Closed -$1.49M
MAAC
133
DELISTED
Montes Archimedes Acquisition Corp. Class A Common Stock
MAAC
– –
-2,000,000
Closed -$18.7M
2 3 4 5
6

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q4 2021 Portfolio in Review

As of Q4 2021, Deerfield Management held 155 positions worth $4.77B, down 7% from $5.12B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Deerfield Management withdrew a net $1.35B in Q4 2021, closing 28 positions and reducing 21 holdings. Its most notable exit was Acceleron Pharma, an estimated $25M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 66% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Deerfield Management opened a new position in Esperion Therapeutics worth $25M.

  • Deerfield Management's largest Q4 2021 buy was Esperion Therapeutics: 5,000,000 shares worth $25M.
  • Deerfield Management added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2021, an estimated $89.6M increase.
  • Deerfield Management's biggest Q4 2021 reduction was BioDelivery Sciences International, Inc., cutting an estimated $30.8M.
  • Deerfield Management fully exited Acceleron Pharma in Q4 2021, selling an estimated $25M.
  • Deerfield Management's ten largest holdings make up 40% of its $4.77B portfolio in Q4 2021.
  • Deerfield Management opened 23 new positions and closed 28 in Q4 2021.
  • Deerfield Management's portfolio value fell 7% quarter-over-quarter to $4.77B.

Based on Deerfield Management's 13F filing for Q4 2021, filed 14 Feb 2022.